Your browser doesn't support javascript.
loading
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Jang, Jeong Won; Bae, Si Hyun; Choi, Jong Young; Oh, Hyun Jong; Kim, Min Soo; Lee, So Yeon; Kim, Chang Wook; Chang, U Im; Nam, Soon Woo; Cha, Sang Bok; Lee, Young Joon; Chun, Ho Jong; Choi, Byung Gil; Byun, Jae Young; Yoon, Seung Kew.
Afiliación
  • Jang JW; Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, #505 Banpodong, Seocho-ku, 137-040, Seoul, South Korea.
Cancer Chemother Pharmacol ; 59(1): 9-15, 2007 Jan.
Article en En | MEDLINE | ID: mdl-16614848
PURPOSE: Hepatocellular carcinoma (HCC) invading the portal vein is a medical challenge. We evaluated the therapeutic efficacy of a combination of transarterial and systemic chemo-infusion for large HCC with portal vein thrombosis (PVT) compared with conservative management. PATIENTS AND METHODS: This was a case-control cohort study of 103 consecutive patients with Child-Pugh class A who had a large (>10 cm) HCC with PVT. The patients were assigned to receive either combined transarterial epirubicin (50 mg/m(2)) plus cisplatin (60 mg/m(2)) chemo-lipiodolization and systemic 5-fluorouracil (200 mg/m(2)) chemo-infusion (ECF regimen) at monthly intervals (n=80) or conservative management (n=23). RESULTS: The objective tumor response (21.3 vs. 0%, P=0.011) and overall survival (8.7 vs. 3.5 months, P<0.001) were significantly better in the treatment group than in the conservative group. The prognostic factors for survival were tumor type (P=0.007), bilobar involvement (P=0.001), distant metastasis (P=0.009) and objective tumor response (P<0.001) for the treatment group. Survival benefits with the treatment were also maintained in each subgroup after stratification of these variables. CONCLUSIONS: This study suggests that when the hepatic function is preserved, a therapeutic strategy could be more beneficial than conservative management for such a large extensive HCC. As a therapeutic option, a combination therapy using ECF regimen may provide a significantly better tumor response and survival benefit in patients with large HCC invading the portal vein.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vena Porta / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Año: 2007 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Alemania
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vena Porta / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Año: 2007 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Alemania